Loading...
•
Dec 31, 2022
Ashland Q1 2023 Earnings Report
Ashland's first quarter of fiscal year 2023 financial results were reported.
Key Takeaways
Ashland reported sales of $525 million, a 3% increase year-over-year. Net income was $40 million, and income from continuing operations was $42 million, or $0.76 per diluted share. Adjusted EBITDA was $108 million, up 2% from the prior year.
Sales increased by 3% to $525 million compared to the prior-year quarter.
Net income was $40 million, while income from continuing operations reached $42 million, or $0.76 per diluted share.
Adjusted income from continuing operations, excluding intangibles amortization expense, was $54 million, or $0.97 per diluted share.
Adjusted EBITDA increased by 2% to $108 million from $106 million in the prior-year quarter.
Ashland
Ashland
Ashland Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comPersonal Care Revenue
CapyFin.comSpecialty Additives Revenue
CapyFin.comIntermediates Revenue
CapyFin.com Forward Guidance
Ashland continues to expect sales in the range of $2.5 billion to $2.7 billion for fiscal year 2023. In addition, the company continues to expect Adjusted EBITDA to be within the prior outlook range of $600 million to $650 million, with the current forecast models indicating earnings below the mid-point of that range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income